Cardiovascular therapies and neuromodulation devices by CVRx
Barostim device rollout gives Prairie Cardiovascular patients novel heart failure therapy option
CVRx announced its support for Prairie Cardiovascular and HSHS St. Elizabeth Hospital as the institutions completed their first Barostim implant procedure. The new device therapy offers patients ...
CVRx to present Barostim integration strategies at AAHFN Annual Meeting
CVRx is set to lead a session on integrating Barostim therapy into comprehensive heart failure programs at this week's AAHFN Annual Meeting. The event, which will take place on Wednesday, June ...
Barostim adoption in heart failure management advances, led by CVRx
CVRx will address the integration of Barostim technology into heart failure care at the upcoming American Association of Heart Failure Nurses (AAHFN) Annual Meeting. The session will feature ...
CVRx partners with Huntsville Hospital for first Barostim implant, expanding device therapy options
CVRx collaborated with Huntsville Hospital and a multidisciplinary team to complete the hospital's first Barostim implant. The partnership included heart failure and cardiovascular surgery teams, ...
Barostim access broadens with RWJBarnabas Health and CVRx partnership
CVRx announced an expansion of access to its Barostim therapy for patients with heart failure, supported by RWJBarnabas Health. The company recognized Dr. Kulpreet Barn, Dr. Jagpreet Grewal, Dr. ...
CVRx commends Christus Trinity Mother Frances on 10th Barostim heart failure implant milestone
CVRx announced that Christus Trinity Mother Frances has reached its tenth successful Barostim implant for patients with heart failure. This milestone highlights the dedication of Dr. Todd ...
CVRx brings Michael Dale onto board to leverage leadership in medical devices
CVRx has appointed Michael Dale as a new member of its Board of Directors. Dale brings decades of leadership experience in the medical device sector and is known for a strong track record in ...
CVRx celebrates 50th Barostim implant milestone at Wellstar Kennestone
CVRx has congratulated Dr. Ryan Burke, Dr. Brian Howard, Dr. Latif Bikak, and the team at Wellstar Kennestone for reaching the milestone of their 50th Barostim implant. This accomplishment ...
CVRx targets clinical integration of Barostim with hands on symposium at AAHFN2026
CVRx has announced its participation in AAHFN2026, where the company will host an interactive dinner symposium focused on the role of Advanced Practice Providers in patient selection and the ...
CVRx publishes BENEFIT-HF trial design in peer-reviewed journal
CVRx has announced the publication of the BENEFIT-HF trial design paper in the Journal of Cardiac Failure. The article presents the methodology for a prospective, randomized, controlled, ...
Clinical research teams accelerate progress in treatment options, CVRx asserts
CVRx recognizes the important role of researchers and healthcare professionals who advance the science underpinning better patient care. The company emphasized that clinical trials are essential ...
CVRx marks 25th Barostim implant milestone at UNC Medical Center Chapel Hill
CVRx has announced the successful completion of the 25th Barostim implant at UNC Medical Center in Chapel Hill. The accomplishment recognizes the contributions of Dr. William Tripp Mostertz, ...
Humana expands Barostim therapy access via Medicare Advantage, CVRx secures national deal
CVRx has announced that Humana will issue a Medicare Advantage coverage policy for Barostim therapy, with the policy set to become effective on May 1, 2026. Humana is one of the largest national ...
CVRx revenue rises 20 percent in first quarter as U.S. operations expand
CVRx reported a 20 percent increase in total revenue for the first quarter, signaling robust growth compared to the same period last year. The company also recorded a 22 percent surge in U.S. ...
CVRx launches landmark BENEFIT-HF trial for cardiac device research
CVRx has announced the first patient enrollment in the BENEFIT-HF trial at North Central Heart, a division of the Avera Heart Hospital in Sioux Falls, South Dakota. This groundbreaking trial, ...
CVRx reports Barostim therapy boosts quality of life for heart failure patients
CVRx announced that Dr. Savitri Fedson has shared a real-world account highlighting the impact of Barostim therapy on heart failure patients. According to Dr. Fedson, patients using Barostim have ...
Methodist University Hospital completes first Barostim implant with CVRx collaboration
CVRx and Methodist University Hospital have announced the successful completion of the hospital's first Barostim implant, a novel device therapy aimed at improving symptoms for patients with heart ...
CVRx promotes Barostim therapy as new option for heart failure patients at ISHLT2026
CVRx is spotlighting its Barostim device therapy at ISHLT2026, emphasizing its potential to improve exercise capacity and quality of life for individuals with heart failure. The company ...
Lawnwood Medical Center achieves milestone with 15th Barostim therapy, CVRx confirms
CVRx announced that Dr. Philip Seibel and the team at Lawnwood Medical Center have successfully completed their 15th Barostim implant. This milestone reflects sustained efforts to provide ...
CVRx unveils Barostim session on neurohormonal targeting at ISHLT2026
CVRx is set to present a session titled Barostim: Flipping the Parasympathetic Switch at the upcoming ISHLT2026 conference. The session will focus on how Barostim technology complements ...
CVRx expects robust 20 percent revenue growth in preliminary Q1 results
CVRx has announced its preliminary first-quarter 2026 financial results, projecting revenue between 14.7 million and 14.8 million dollars and indicating approximately 20 percent growth compared to ...
